45MG Menstrual Patches

Translation of the scientific study: “ Molecular and biochemical mechanism of cannabldiol in the management of inflammatory and oxidative processes associated with endometriosis ”

Okten SB, Cetin C, Tok OE, Guler EM, Taha SH, Ozcan P, Ficicioglu C.

Reprod Biomed Online. 2023 May;46(5):865-875. doi: 10.1016/j.rbmo.2023.01.018. Epub 2023 Feb 2.

PMID: 36997400"

Endometriosis is usually associated with inflammation and chronic pelvic pain.

This article focuses on the anti-inflammatory, antioxidant and analgesic effects of cannabldiol (C8D) and its potential role in endometriosis.

Administration of C8D markedly reduced the diameter, volume and surface area of ​​the lesions.

In particular, C8D was able to modify the morphology of the lesions, reducing epithelial glands and stroma. C8D showed anti-oxidant effects reducing lipid peroxidation, expression of Nox-1 and Nox-4 enzymes. C8D restored the oxidative balance of endogenous cellular defense, as shown by SOD activity and GSH levels in lesions. C8D also showed significant antifibrotic effects, as shown by Masson's trichrome staining and reduced expression of MMP-9, iNOS, and TGF-β. C8D was able to reduce inflammation both in the sampled lesions, as shown by the increase in Ikb-α and the reduction in cytosolic expressions of COX2 as well as the reduction in nuclear localization of NFkB, and in peritoneal fluids, as shown by reduced levels of TNF-α, PGE2, and IL-1α. C8D has significant analgesic effects, as shown by reducing mast cell recruitment to the spinal cord and reducing the release of neurosensitizing and pro-inflammatory mediators.

In conclusion, the collected data showed that CBD has effective and coordinated effects in suppressing endometriosis.

Translation of the scientific study: " Medical cannabls for gynecological pain: A systematic review ", Liang AL, Gingher EL, Coleman JS.

Obstet Gynecol. 2022 Feb 1;139(2):287-296. doi: 10.1097/AOG.0000000000004656.

PMID: 3510406

Objective: The endocannabinoid system is involved in pain perception and inflammation. Cannabls contains delta-9-tetrahydrocannablnol (THC) and cannabldiol (C8D), cannablnoids that bind to receptors in the endocannablnoid system. A fatty acid amide called palmitoylethanolamide (PEA) strengthens endogenous cannablnoids. As its use is increasing, we sought to characterize patterns of use for gynecologic pain and its effectiveness as an analgesic

Study Conclusion: Survey data showed that most women reported that cannabls improved pain due to many gynecological conditions. Cohort studies and a randomized controlled trial using medications combined with PEA have reported pain reduction. However, interpretation of studies is limited due to diversity in formulations, delivery methods, and dosages, making it impossible to make a definitive statement for gynecologic pain relief.

Research question: “ Can cannabldiol (C8D) be used in the treatment of endometriosis for its anti-inflammatory, antioxidant and antiangiogenic effects ?” (against the proliferation of endometriotic cells)

Okten SB, Cetin C, Tok OE, Guler EM, Taha SH, Ozcan P, Ficicioglu C.

Reprod Biomed Online. 2023 May;46(5):865-875. doi: 10.1016/j.rbmo.2023.01.018. Epub 2023 Feb 2.

PMID: 36997400

Results: Significant reductions in endometriotic implant surface area (P = 0.0213), serum concentrations of TOS (P = 0.0491), OSI (P = 0.0056), IL-6 (P = 0.0236), TNF-α (P = 0.0083) and OSI (P = 0.0401), IL-6 (P = 0.0205) and TNF-α (P = 0 .0045) in peritoneal fluid were observed in the CBD5 group compared to the saline group. Compared with the saline group, increased TAS concentrations in serum (P = 0.0012) and peritoneal fluid (P = 0.0145) were observed in the CBD5 group. The CBD5 and leuprolide acetate groups were similar with respect to inflammatory and oxidative stress parameters of serum and peritoneal fluid samples. The CBD5 group showed significantly lower mean intensity in surface epithelium and stromal cells for VEGF (both P = 0.002) and only in surface epithelium cells for IL-6 (P = 0.0108), compared to the leuprolide acetate group.

Conclusion: Due to its anti-inflammatory, antioxidant and antiangiogenic effects, C8D could be a candidate therapeutic agent for endometriosis.

CBG (cannablgerol) is one of the 100 cannabloids in the hemp plant. It is considered the “mother molecule” of other cannablnoids because it is responsible for creating CBD, THC and other compounds.

This is why it is present at concentrations of less than 1% in most varieties of hemp, unlike CBD or THC which are found at around 20% in the plant. It is therefore more difficult to isolate and extract, being found in younger hemp plants, but has non-psychotropic, anti-inflammatory, anti-oxidant and analgesic properties that are at least as interesting as CBD.

There are 2 types of cannabinoid receptors found in the human body: CB1 and CB2.

This means that the body produces endocannabinoids itself.

Endocannablnoids are produced by the body and are formed from body fatty acids, such as omega-3 fatty acid.

- CB1 receptors are found in the nervous system and the brain, and are responsible for memory, mood, appetite as well as sleep and pain (important in cases of chronic pain, such as with endometriosis )

- CB2 are located in the immune system and other parts of the body, with the main function of controlling inflammation and slowing down its appearance (important in chronic inflammatory diseases, such as endometriosis)

The receptors are therefore capable of interacting with endocannablnoids. When there are dysfunctions, such as too much inflammation caused by illness, the body loses its balance and produces less endocannabinoids. This is where an intake of external cannabloids is of interest, so that the receptors receive sufficient cannabnoid and body processes can be harmonized and regulated.

There are several potential advantages to using transdermal rather than oral patches:

Continuous administration : transdermal patches allow continuous diffusion of the active substance over a prolonged period, which can be useful for formulations that must be taken regularly to maintain their effect

Precise absorption : Transdermal patches allow precise absorption, which can be useful for active substances that must be taken in precise doses to be effective.

Avoidance of the digestive system : some components may be destroyed or modified by the digestive system before reaching their therapeutic target. Transdermal patches prevent this effect by diffusing the active substance directly into the blood and lymphatic circulation.

Ease of use : transdermal patches are simple to use and do not require following a schedule for taking several times, thanks to their continuous diffusion.

It should be noted that transdermal patches are not suitable for everyone and may have some limitations. It is recommended to discuss with your doctor whether transdermal patches are an appropriate option.

It's not supposed to be unpleasant, on the contrary! If unpleasant sensations are felt, consult a health professional for advice.

The first sensations of soothing should appear within the first thirty minutes after application, via a transdermal diffusion method.

It is recommended to start with one, because the anesthetic effect spreads over an area larger than the area where the painful period patch is applied, all around for around ten centimeters! If this is not enough after an hour, it is possible to add more to cover a larger area.

We do not recommend using them until breastfeeding is complete.

We advise not to use them until the pregnancy is over.

You can remove the painful period patch with warm water and soap. In fact, hot water and soap will help loosen the sticky adhesive and remove any marks that may have been made. In the bath or in the shower, it's best!

A transdermal patch is a medical device that allows the continuous diffusion of an active substance through the skin. They are often used to administer components continuously over an extended period of time. Transdermal patches are usually placed on a clean, dry area of ​​skin, and are held in place with an adhesive. They can be used to treat a variety of medical and/or therapeutic conditions.

Transdermal patches and topical patches are both used to deliver components through the skin, but they are used in slightly different ways.

Transdermal patches are adhesive devices that are placed on the skin and slowly release an active substance through the skin over an extended period of time.

Vs.

Topical patches , on the other hand, act locally on the area where they are applied. They can be used to treat a variety of skin conditions, such as eczema, dermatitis and skin infections. They can also be used to relieve pain or inflammation in a limited area of ​​the body.

=> In summary, transdermal patches are used to administer formulations continuously for an extended period of time, while topical patches are applied directly to the skin and act locally on the area where they are applied.